Radiation-Induced Fibrosis Treatment Market

Radiation-Induced Fibrosis Treatment Market Overview

According to the latest research by Future Market Insights, Radiation-Induced Fibrosis Treatment market is set to witness a 5.6% growth during the year 2021-2031. The market is expected to witness growth owing to increase in number of patients going through radiotherapy

or chemotherapy and the growing utilization of novel drug delivery methods like transdermal patches & combination therapies. Moreover, the market is furthermore influenced by technology advancements to discover novel high potential drugs, hence creating lucrative opportunities in the market.

What is Driving Demand for Radiation-Induced Fibrosis Treatment

Increasing occurrence of cancer and developments in research and development of medicines will help in boosting the development of the market.

Moreover, strong research and development in oncology treatment, the increase in the occurrence of cancer cases, growing preference toward chemotherapy for the treatment of cancer and the usage of chemotherapy in together with other cancer treatments are expected to drive the growth of radiation-induced fibrosis treatment.

In addition, the demand for the global market for radiation-induced fibrosis treatment is anticipated to grow on account of the increasing occurrence of different types of cancers worldwide.

Growing number of cancer cases, likely to boost Radiation-Induced Fibrosis Treatment Sales

Cancer is one of the leading cause of death across the world. As per the National Institutes of Health (NIH), in 2018, around 1,735,350 new cases of cancer were detected in the United States and 609,640 people died from the disease.

Cancer can be treated by chemotherapy, surgery, hormone therapy, radiation therapy, targeted therapy, stem cell transplantation and precision medicine.

The most common therapy for cancer is chemotherapy; it utilizes drugs to eradicate cancer cells which lead to pain and other problems. Chemotherapy can be used together with other cancer treatments.

Chemotherapy, kills the cancer cells as well as attacks healthy cells which results into side effects such as hair loss, fatigue, nausea, and vomiting. Radiation-induced fibrosis is the late indication of radiation-induced lung disease and is comparatively common following radiotherapy for intrathoracic or chest wall malignancies.

US and Canada Radiation-Induced Fibrosis Treatment Market Outlook

The US and Canada Radiation-Induced Fibrosis Treatment market is expected to observe a robust growth in the market owing to the increasing on account of the presence of various cancer-relief organizations and campaigns in the US and Canada. Also, rising number of cancer cases is expected to boost the market in US.

As per the American Cancer Society’s annual report, around 1.6 million population was affected by cancer in US in 2017 and hence it is expected to occupy the highest market share in the market. In addition, advantageous government initiatives and rise in the number of research partnerships are few of the factors anticipated to increase market growth.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Europe Demand Outlook for Radiation-Induced Fibrosis Treatment

Europe is expected to be second most lucrative region for market owing to several factors. The increasing patient pool leads to a high rate of radiation-induced fibrosis treatment drugs adoption because of rising number of patients with chemotherapeutic associated side effects.

Moreover, the increase in cancer patients, funding by the governmental bodies and focus on merger and acquisition by various key manufacturers is expected to lead to market growth.

Who are the Key Manufacturers and Suppliers of Radiation-Induced Fibrosis Treatment

Some of the leading manufacturers and suppliers of Radiation-Induced Fibrosis Treatment include

• Merck & Co. Inc.
• Galapagos NV
• Biogen
• Bristol-Myers Squibb Company
• Prometic Life Sciences Inc.
• Cipla Inc.
• Pfizer, MediciNova, Inc.
• Boehringer Ingelheim
• F. Hoffmann-La Roche
• FibroGen, Inc.
• Promedior, Inc.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Accord Healthcare
• Zydus Cadila, and others.

The market is moderately competitive with presence of various major players. Technology partnerships and collaborations by the major players in the market with a view to bridge the demand-supply gap is expected to play a key role in development of the market.

Worldwide, they are involved in long term contracts with medical care organizations, and are involving into partnerships and strategic alliances with other players in various nations to extend their business. Also, major players are funding largely in the in the research and development to produce advanced products.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.

The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Key Segments

By Treatment Type:

• Pharmaceuticals
  • Corticosteroids
  • Vitamin E
  • Pirfenidone
  • NSAIDs
• Hyperbaric oxygen
• Physiotherapy
• Microcurrent stimulation

By Route of Administration:

• Oral
• Parenteral

By End User:

• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Others

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa